跳至主要内容
临床试验/NCT03679312
NCT03679312已完成1 期

The Effect of Inhaled Nitric Oxide on Dyspnea and Exercise Tolerance in COPD

University of Alberta1 个研究点 分布在 1 个国家目标入组 140 人开始时间: 2018年9月4日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
140
试验地点
1
主要终点
Peak Oxygen Consumption

研究概览

简要总结

Chronic Obstructive Pulmonary Disease (COPD) is a lung disorder commonly caused by smoking, which makes breathing more difficult. When COPD patients exercise, they are not efficient breathers and this leads to serious breathing difficulties, which often causes these patients to stop exercise at low intensities. Even though patients with a mild form of COPD have relatively well preserved lung function, they still have inefficient breathing during exercise. The investigators think that these patients have problems exchanging fresh gas (i.e., oxygen) into the blood stream because of poor lung blood vessel function. The investigators will test whether inhaled medications, specifically nitric oxide, can improve lung blood vessel function and decrease breathing difficulties during exercise. With this research, the investigators will understand more about breathing efficiency and lung blood vessel function in patients with COPD, and find out whether improving lung blood vessel function helps COPD patients breathe easier and exercise longer. Understanding the reasons behind the feeling of difficult breathing may lead to more effective therapy and improved quality of life in COPD patients.

详细描述

Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disorder typically caused by smoking and is characterized by airway obstruction. Exertional dyspnea (perceived breathlessness) is a hallmark of COPD regardless of severity and is the primary reason for exercise intolerance even in patients with mild COPD (defined using spirometric criteria as a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.70 and a FEV1 ≥ 80%). Dyspnea in COPD has been shown to profoundly reduce patient quality of life, physical activity, and impair patients' ability to complete day-to-day tasks. Previous work in mild COPD has demonstrated that exertional dyspnea is the result of increased work of breathing during exercise, and that this increased work of breathing comes from: 1) an exaggerated ventilatory response to exercise (i.e. increased minute ventilation relative to carbon dioxide production, V̇E/V̇CO2), and 2) airflow limitation (i.e. expiratory flow limitation and resulting dynamic hyperinflation). A great deal of work has focused on improving airflow limitation in COPD; however, very little has been done to understand and treat the exaggerated ventilatory response to exercise in COPD.

Several previous studies in COPD have consistently shown an elevated ventilatory response (i.e. greater V̇E/V̇CO2) during exercise. The elevated V̇E/V̇CO2 response to exercise appears to be clinically important, as it independently predicts mortality in COPD and indicates that physiological abnormalities beyond airflow obstruction are important in determining disease severity, dyspnea, and risk of death. This increased V̇E/V̇CO2 in COPD appears to be secondary to increased deadspace ventilation(i.e. sections of the lung with ventilation, but no perfusion), and this increased deadspace ventilation results in a compensatory increase in total minute ventilation (i.e. increased V̇E/V̇CO2) to maintain effective alveolar ventilation and arterial blood gas homeostasis.

The underlying mechanism(s) for the increased deadspace ventilation and V̇E/V̇CO2 during exercise in mild to moderate COPD is currently unclear; however, pulmonary microvascular abnormalities and hypoperfusion of pulmonary capillaries are potential pathophysiologic mechanisms. Mild to moderate COPD patients have reduced pulmonary microvascular blood flow in nonemphysematous lung regions, which has led researchers to conclude that the low pulmonary perfusion in an intact pulmonary vascular bed is likely the result of pulmonary vascular dysfunction. Ventilation-perfusion (V̇A/Q̇) data in mild and moderate COPD shows substantial V̇A/Q̇ inequality at rest, with the V̇A/Q̇ distribution skewed towards regions of high V̇A/Q̇, which is indicative of increased deadspace. Consistent with this capillary hypoperfusion hypothesis, our recent work has shown a blunted pulmonary capillary blood volume response to exercise in mild COPD, when compared to age- and height-matched non-smoking controls. Importantly, the low pulmonary capillary blood volume was associated with increased V̇E/V̇CO2 during exercise, suggesting that low pulmonary perfusion (i.e. reduced pulmonary capillary blood volume) leads to increased deadspace.

Inhaled nitric oxide (NO) is commonly used to test for pulmonary vasodilatory responses in patients with pulmonary arterial hypertension (PAH), as it increases NO bioavailability and improves pulmonary vascular function. Previous work in PAH and heart failure (HF) patients has shown that standard doses (20-40 parts per million (ppm)) of inhaled NO can reduce pulmonary vascular resistance and increase peak oxygen consumption (V̇O2peak). If inhaled NO can reduce vascular dysfunction and increase perfusion in mild and moderate COPD, this would result in a reduction in V̇E/V̇CO2 and improved exercise tolerance.

STUDY PURPOSE

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • Individuals with significant cardiovascular, metabolic, neuromuscular or any other disease
  • Individual with musculoskeletal injuries
  • Individuals currently on oral steroids (i.e. prednisone), phosphodiesterase type 5 (PDE5) inhibitors or supplemental O2 therapy

研究组 & 干预措施

COPD Group

Experimental

COPD to receive either placebo or inhaled nitric oxide (40ppm)

干预措施: Nitric Oxide (Drug)

COPD Group

Experimental

COPD to receive either placebo or inhaled nitric oxide (40ppm)

干预措施: Placebo (Drug)

Control Group

Experimental

Control group to receive either placebo or inhaled nitric oxide (40ppm)

干预措施: Nitric Oxide (Drug)

Control Group

Experimental

Control group to receive either placebo or inhaled nitric oxide (40ppm)

干预措施: Placebo (Drug)

结局指标

主要结局

Peak Oxygen Consumption

时间窗: Within 20-25 minutes post-dose

Peak oxygen consumption will be defined as the highest O2 uptake (reported in ml/kg/min) obtained during a 20 s period during the test.

Peak Workload

时间窗: Within 20-25 minutes post-dose

Peak workload will be defined as the highest wattage obtained during a 20 s period during the test.

次要结局

  • Dyspnea (breathlessness)(Assessed every 2-minutes until completion of the exercise trial; anticipating ~10-14 minute tests)
  • Pulmonary artery systolic pressure(Assessed for five consecutive cardiac cycles and are measured in triplicate during the cardiac ultrasound trial. This will be completed within 4 weeks of enrollment in the study.)
  • Emphysema severity score(Emphysema severity score assessed by computed tomography. This will be completed within 4 weeks of enrollment in the study.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验